Actively Recruiting
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2025-03-11
20
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.
CONDITIONS
Official Title
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Untreated locally advanced cervical cancer patients with clear pathological diagnosis
- 2019 FIGO stage IIIB-IVA; for stage IIIC, metastatic lymph nodes must be at least 1.5 cm in short diameter
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy greater than 6 months
- Able to tolerate concurrent chemoradiotherapy as assessed by researchers
- No obvious active bleeding
- Adequate hematological, renal, and hepatic functions
- No other malignancies present
- Female subjects of childbearing potential must have a negative pregnancy test and agree to use reliable contraception during the trial
- Voluntarily signed informed consent
You will not qualify if you...
- Having other malignancies besides cervical cancer
- Presence of metastatic or recurrent disease
- Previous treatment for cervical cancer before enrollment
- Severe chronic diseases such as diabetes or hypertension, or acute infections
- Impaired blood, kidney, or liver function including:
- Hemoglobin below 9.0 g/dl
- Neutrophils below 2000 cells/µl or leukocytes below 4 x 10^9/L
- Platelets above 100 x 10^9/L
- Serum ALT/AST more than 2.5 times the upper normal limit
- Serum total bilirubin above 1.5 times the upper normal limit
- Serum urea nitrogen more than 1.5 times the upper normal limit
- Serum creatinine more than 1.5 times the upper normal limit
- Heart conditions like arrhythmia, myocardial ischemia, severe AV block, heart failure, or severe valve disease
- Uncontrolled mental illnesses
- Pregnant or breastfeeding women
- Currently participating in other clinical trials
- Considered unsuitable for enrollment by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
Research Team
Y
Yuanjie Cao
CONTACT
C
Chen Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here